# Halo Neuro

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/halo-neuro

- Industry: Consumer Products
- Headquarters: San Francisco, US
- Website: www.haloneuro.com
- Total disclosed funding: $24M
- Latest round: Series B (Nov 16, 2017)
- Investors on record: 7

## About

Halo Neuro, Inc., based in the US, specializes in advanced neurotechnology solutions that develop non-invasive neurostimulation devices aimed at improving neurological health and patient outcomes.Founded in 2013 and headquartered in San Francisco, US, Halo Neuro, Inc. is dedicated to pioneering neurotechnology. The company has successfully secured funding, recently raising USD 1 million in April 2018 from Future Planet Capital, bringing the total amount raised to USD 1 million across eight deals.Halo Neuro specializes in advanced neurotechnology solutions, focusing on the development and application of neurostimulation devices designed to address various neurological conditions. Their flagship product is a non-invasive neurostimulation device that employs technologies to modulate brain activity, providing therapeutic benefits for conditions such as chronic pain, anxiety, and depression. Released in recent years, this product has garnered attention in both clinical and consumer markets, appealing to healthcare providers, rehabilitation centers, and individual users seeking alternative treatments. The company aims to enhance patient outcomes and quality of life by offering innovative solutions that are scientifically backed and user-friendly. Halo Neuro’s products are marketed primarily in North America and Europe, targeting healthcare institutions, private clinics, and direct consumers, thereby establishing a diverse client base across multiple geographical regions.Halo Neuro generates revenue through the sale of its neurostimulation devices and related services, employing a direct-to-consumer model alongside partnerships with healthcare providers. The company’s transactions typically involve clients purchasing their flagship products either outright or through subscription-based models for ongoing access to software updates and additional services. This structure facilitates a steady revenue stream while encouraging continuous engagement with users through follow-up services and enhancements. Pricing plans for their devices accommodate both individual consumers and institutional clients, allowing for scalable solutions that meet varying needs. By leveraging both direct sales and B2B partnerships, Halo Neuro ensures a comprehensive approach to market penetration while maintaining a focus on delivering value to their customers.Halo Neuro plans to leverage its recent funding of USD 1 million raised in April 2018 to further develop new neurostimulation products and expand its market presence. The company is targeting new geographic regions in North America and Europe, with strategic plans to introduce additional therapies aimed at addressing a broader range of neurological conditions. Additionally, the funds will support research and development efforts to enhance existing product lines and potentially explore new applications of neurotechnology.

## Funding rounds

- Series B, Nov 16, 2017, $13M — TPG, Lux Capital, Uncork Capital, Xfund, JAZZ Venture Partners
- Series A, Feb 10, 2016, $9M — Lux Capital, Andreessen Horowitz, Uncork Capital, Xfund, JAZZ Venture Partners
- Seed, May 1, 2014, $1.5M — Andreessen Horowitz, Uncork Capital, Kima Ventures
- Seed, Jul 22, 2013, $0.1M — Lux Capital, Kima Ventures

## Investors

- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Seed, Series A, Series B
- Kima Ventures (https://capitalatlas.ai/funds/kima-ventures) — Seed
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Seed, Series A
- Uncork Capital (https://capitalatlas.ai/funds/uncork-capital) — Seed, Series A, Series B
- Xfund (https://capitalatlas.ai/funds/xfund) — Series A, Series B
- JAZZ Venture Partners (https://capitalatlas.ai/funds/jazz-venture-partners) — Series A, Series B
- TPG (https://capitalatlas.ai/funds/tpg) — Series B